Relapse risk of endometrial hyperplasia after treatment with the levonorgestrel‐impregnated intrauterine system or oral progestogens

OBJECTIVE: To investigate relapse rates after the successful treatment of patients with non‐atypical endometrial hyperplasia who were randomised to either a levonorgestrel‐impregnated intrauterine system (LNG‐IUS; Mirena(®)) or two regimens of oral medroxyprogesterone acetate (MPA) after primary his...

Descripción completa

Detalles Bibliográficos
Autores principales: Ørbo, A, Arnes, M, Vereide, AB, Straume, B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Gynaecological Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5215722/
https://www.ncbi.nlm.nih.gov/pubmed/26630538
http://dx.doi.org/10.1111/1471-0528.13763

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5215722/
https://www.ncbi.nlm.nih.gov/pubmed/26630538
http://dx.doi.org/10.1111/1471-0528.13763

Ejemplares similares